A Double-blind Randomized Study Comparing Imipramine with Fluvoxamine in Depressed Inpatients

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2004 Jul 10

PMID 15243735

Citations 4

Authors

Walter W Van den Broek

Tom K Birkenhager

Paul G H Mulder

Jan A Bruijn

Peter Moleman

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the efficacy of imipramine and fluvoxamine in inpatients from two centers suffering from a depressive disorder according to DSM IV criteria.

Methods: The study included 141 patients with a depressive disorder according to DSM IV criteria. After a drug-free and placebo run-in period of 1 week, patients were randomized to imipramine or fluvoxamine; doses of both drugs were adjusted to a predefined target blood level. Efficacy was evaluated 4 weeks after attaining predefined adequate plasma level.

Results: The mean age of the study group (47 males, 94 females) was 51.8 (range 19-65) years. Of these 141 patients, 56 had episode duration longer than 1 year, 48 had mood congruent psychotic features, and 138 patients received medication. Seven patients did not complete the medication trial. The total number of patients using concurrent medication was 12/138 (8.6%). On the primary outcome criteria patients on imipramine improved significantly better on the change of illness severity score of the CGI (chi2 exact trend test=4.089, df=1, P=-0.048). There was no significant difference in 50% or more reduction on the HRSD, the other primary outcome criterion. On the secondary outcome criteria the mean reduction of the HRSD scores was significantly larger in the imipramine group than in the fluvoxamine group (mean difference=3.1, standard error (SE)=1.4, t=2.15, df=136, P=0.033). There was no significant difference in the number of patients with an HRSD < or =7 at the final evaluation.

Conclusions: In depressed inpatients imipramine is more efficacious than fluvoxamine. Both drugs were well tolerated by all patients.

Citing Articles

Pharmacological treatment for psychotic depression.

Kruizinga J, Liemburg E, Burger H, Cipriani A, Geddes J, Robertson L Cochrane Database Syst Rev. 2021; 12:CD004044.

PMID: 34875106 PMC: 8651069. DOI: 10.1002/14651858.CD004044.pub5.

Early improvement as a predictor of eventual antidepressant treatment response in severely depressed inpatients.

Vermeiden M, Kamperman A, Vulink M, Van den Broek W, Birkenhager T Psychopharmacology (Berl). 2014; 232(8):1347-56.

PMID: 25338776 DOI: 10.1007/s00213-014-3765-1.

Fluvoxamine versus other anti-depressive agents for depression.

Omori I, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H Cochrane Database Syst Rev. 2010; (3):CD006114.

PMID: 20238342 PMC: 4171125. DOI: 10.1002/14651858.CD006114.pub2.

Imipramine dose in relation to therapeutic plasma level: are clinical trials using imipramine as a positive control flawed?.

Birkenhager T, Van den Broek W, Moleman P, Vulto A, Bruijn J Psychopharmacology (Berl). 2005; 181(3):595-9.

PMID: 16133127 DOI: 10.1007/s00213-005-0098-0.

References

Bruijn J, Moleman P, Mulder P, Van Den Broek W, van Hulst A, van der Mast R . A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl). 1996; 127(3):231-7. View

Lydiard R, Laird L, MORTON Jr W, Steele T, Kellner C, Laraia M . Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70. View

Niklson I, Reimitz P, Sennef C . Factors that influence the outcome of placebo-controlled antidepressant clinical trials. Psychopharmacol Bull. 1997; 33(1):41-51. View

March J, Kobak K, Jefferson J, Mazza J, Greist J . A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatry. 1990; 51(5):200-2. View

Anderson I . Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000; 58(1):19-36. DOI: 10.1016/s0165-0327(99)00092-0. View

. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord. 1990; 18(4):289-99. DOI: 10.1016/0165-0327(90)90081-i. View

Sackeim H, Prudic J, Devanand D, Decina P, Kerr B, MALITZ S . The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990; 10(2):96-104. DOI: 10.1097/00004714-199004000-00004. View

Hartter S, WETZEL H, Hammes E, Torkzadeh M, Hiemke C . Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit. 1998; 20(4):446-9. DOI: 10.1097/00007691-199808000-00016. View

Lapierre Y, Browne M, Horn E, Oyewumi L, Sarantidis D, Roberts N . Treatment of major affective disorder with fluvoxamine. J Clin Psychiatry. 1987; 48(2):65-8. View

10.

Glassman A, Perel J, Shostak M, Kantor S, Fleiss J . Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry. 1977; 34(2):197-204. DOI: 10.1001/archpsyc.1977.01770140087010. View

11.

Kasper S, Moller H, Montgomery S, ZONDAG E . Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine. Int Clin Psychopharmacol. 1995; 9 Suppl 4:3-12. DOI: 10.1097/00004850-199501004-00001. View

12.

Fabre L, Birkhimer L, Zaborny B, Wong L, Kapik B . Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int Clin Psychopharmacol. 1996; 11(2):119-27. View

13.

Prudic J, Haskett R, Mulsant B, Malone K, Pettinati H, Stephens S . Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996; 153(8):985-92. DOI: 10.1176/ajp.153.8.985. View

14.

Itil T, Shrivastava R, Mukherjee S, COLEMAN B, MICHAEL S . A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol. 1983; 15 Suppl 3:433S-438S. PMC: 1427663. DOI: 10.1111/j.1365-2125.1983.tb02134.x. View

15.

Spigset O, Martensson B . Fortnightly review: drug treatment of depression. BMJ. 1999; 318(7192):1188-91. PMC: 1115588. DOI: 10.1136/bmj.318.7192.1188. View

16.

Zohar J, Keegstra H, Barrelet L . Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Hum Psychopharmacol. 2003; 18(2):113-9. DOI: 10.1002/hup.442. View

17.

Guelfi J, Dreyfus J, Pichot P . A double-blind controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol. 1983; 15 Suppl 3:411S-417S. PMC: 1427660. DOI: 10.1111/j.1365-2125.1983.tb02131.x. View

18.

Roose S, Glassman A, Attia E, Woodring S . Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994; 151(12):1735-9. DOI: 10.1176/ajp.151.12.1735. View

19.

Hirschfeld R . Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry. 1999; 60(5):326-35. DOI: 10.4088/jcp.v60n0511. View

20.

Walczak D, APTER J, Halikas J, Borison R, CARMAN J, Post G . The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry. 1996; 8(3):139-51. DOI: 10.3109/10401239609147751. View